The new drug registration of step pharmaceutical subsidiary was terminated, and 7.6 million R & D expenses have been invested

BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious

BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.

Youwe Biotech Bags Nearly CNY 100 Mn in Series B Financing Round

Founded in 2017, Youwe Biotech, specializing in dissolving microneedle technology, will continue with the commercialization of its products with the fresh proceeds.

Dialysis Provider Dakang Medical Raised CNY 400 Million Yuan in Series E Round.

This financing round was led by Ganjiang Kai Investment, a state-owned investment platform in Ganjiang, Jiangxi Province, and was followed by Central Enterprises Poor Regions Industry Investment Fund Co., and Neovision Capital.

Biotech Firm ImmuneOnco Submitted Listing Application on the Main Board of HKEX

ImmuneOnco, focusing on developing new-generation tumor immunotherapeutic, will further accelerate the development of other promising drug candidates targeting checkpoints of innate and adaptive immunity.

Lvzhu Biopharmaceutical's Completed its Third Funding Round of The Year

Lvzhu finished its Series C funding round, marking its success of gaining three funding rounds within 12 months. Its exploration of listing in Hong Kong Stock Exchange marks the company's potential, as supported by CICC.